New Frontiers in Chemical Biology: Enabling Drug Discovery

New Frontiers in Chemical Biology: Enabling Drug Discovery

Hardback Rsc Drug Discovery

Edited by Mark E. Bunnage, Series edited by David E. Thurston, Series edited by David Fox, Series edited by Ana Martinez, Series edited by David P. Rotella, Series edited by Professor Robin Ganellin, Contributions by Adam Nelson, Contributions by Martin Fisher, Contributions by Ben Davis, Contributions by L. E. Edgington

$190.73
List price $208.95
You save $18.22 (8%)

Free delivery worldwide
Available
Dispatched in 2 business days
When will my order arrive?

  • Publisher: Royal Society Of Chemistry
  • Format: Hardback | 328 pages
  • Dimensions: 156mm x 234mm x 21mm | 626g
  • Publication date: 17 December 2010
  • Publication City/Country: Cambridge
  • ISBN 10: 184973125X
  • ISBN 13: 9781849731256
  • Edition statement: Edition. ed.
  • Illustrations note: 121 black & white illustrations

Product description

Despite ever-increasing investment in biomedical research, there has been a significant decline in the number of new drug approvals in recent years. In an effort to improve productivity, the drug discovery community has increasingly looked to biotherapeutics such as antibodies, vaccines, nucleic acids, and peptides. Chemical biology is an emerging field at the interface between chemistry and biology. It utilises the tools and techniques of chemical synthesis to study and influence biological systems. Recent developments in this area have great potential in addressing the productivity challenges expressed above. For example, chemical biology studies have already led to the identification of novel targets with exciting therapeutic potential and it is clear that the field will prove a key enabler of target discovery in the future. Moreover, the precise synthetic manipulation of biological molecules involved in many chemical biology approaches is now fuelling a new wave of chemically-modified biologics, 'chemologics', with unique properties. In these, and many other ways, chemical biology is a key discipline within 21st century drug discovery and the purpose of this book is to highlight the most important developments. It provides a valuable resource for scientists in academia and industry who are looking to build their knowledge of this hot topic. The individual chapters cover crucial areas including chemical proteomics, chemical genetics, post-translational modifications, epigenetics, RNA interference, PROTACS, antibody-drug conjugates, and chemologics.

Other people who viewed this bought:

Showing items 1 to 10 of 10

Other books in this category

Showing items 1 to 11 of 11
Categories:

Author information

Mark read chemistry at the University of Durham, completed his DPhil with Professor S.G. Davies at the University of Oxford, and then moved to The Scripps Research Institute to work with Professor K.C. Nicolaou as a NATO postdoctoral fellow. Mark joined Pfizer in the UK as a medicinal chemist in 1996 and since then has assumed a number of roles of increasing responsibility. Mark is currently the Head of Medicinal Chemistry for Pfizer in Sandwich. Mark has broad interests in medicinal chemistry and is an author or inventor on over 50 publications and patents.

Back cover copy

Chemical biology is an emerging field at the interface between chemistry and biology that utilises the tools and techniques of chemical synthesis to study and influence biological systems. Recent developments in this area have great potential in addressing drug discovery productivity challenges. For example, chemical biology studies have already led to the identification of novel targets with exciting therapeutic potential and it is clear that the field will prove a key enabler of improved target discovery in the future. Moreover, the precise synthetic manipulation of biological molecules applicable to many chemical biology approaches is now fuelling a new wave of chemically-modified biologics, 'chemologics', with unique properties. In these, and many other ways, chemical biology is beginning to emerge as a key discipline within 21st century drug discovery and the purpose of this book is to highlight a number of the most important developments. The chapters illustrate the powerful role that chemical genetic and proteomic approaches can play in interrogating biological mechanisms and developing a deeper understanding of how small molecules interact in more complex biological systems. The modulation of stem cell behaviour through small molecules is also discussed and the emerging field of epigenetics. An overview of chemologic approaches includes highlights from the areas of synthetic vaccines and oligonucleotide therapeutics, and additional chapters focus on antibody drug conjugates and DNA-encoded libraries. New Frontiers in Chemical Biology: Enabling Drug Discovery provides a valuable resource for scientists both in industry and academia who are looking to raise their awareness of chemical biology and how it may enable future drug discovery.

Table of contents

Chemical Proteomics; Chemical Genetics; Chemical Biology of Post-Translational; Modifications; Chemical Biology of Epigenetics; RNA Interference; Proteolysis Targeting; himeric Molecules (PROTACS); Antibody-Drug Conjugates; Chemologics: New Therapeutics at the Interface of Chemistry and Biology;